We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$264B
AUM Growth
+$16.6B
(+6.7%)
Cap. Flow
-$3.28B
Cap. Flow
% of AUM
-1.24%
Top 10 Holdings %
Top 10 Hldgs %
18.75%
Holding
3,331
New
118
Increased
1,090
Reduced
1,840
Closed
95
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$1.03B |
| 2 |
Bristol-Myers Squibb
BMY
|
+$649M |
| 3 |
NVIDIA
NVDA
|
+$329M |
| 4 |
AT&T
T
|
+$316M |
| 5 |
Tesla
TSLA
|
+$313M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$474M |
| 2 |
CELG
Celgene Corp
CELG
|
+$421M |
| 3 |
Broadcom
AVGO
|
+$411M |
| 4 |
Netflix
NFLX
|
+$387M |
| 5 |
Apple
AAPL
|
+$372M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.51% |
| 2 | Financials | 14.64% |
| 3 | Healthcare | 13.3% |
| 4 | Consumer Discretionary | 10.29% |
| 5 | Communication Services | 9.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
Minerva Neurosciences
NERV
$199M
| $815K | ﹤0.01% |
14,342
-11,534
| -45% | -$509K |
|
2752
Progyny
PGNY
$2.2B
| $815K | ﹤0.01% |
+29,688
| New | +$712K |
|
|
CVLY
2753
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $811K | ﹤0.01% |
35,211
-2,771
| -7% | -$60.8K |
|
2754
Aldeyra Therapeutics
ALDX
$93.5M
| $810K | ﹤0.01% |
139,382
+64,863
| +87% | +$375K |
|
|
GPX
2755
DELISTED
GP Strategies Corp.
GPX
| $809K | ﹤0.01% |
61,159
+10,918
| +22% | +$135K |
|
2756
Invesco Trust Investment Grade Municipals
VGM
$564M
| $808K | ﹤0.01% |
58,489
| – | – |
|
2757
First Business Financial Services
FBIZ
$595M
| $807K | ﹤0.01% |
30,624
-2,436
| -7% | -$60.4K |
|
2758
Evolus
EOLS
$501M
| $806K | ﹤0.01% |
66,210
+1,194
| +2% | +$16.8K |
|
2759
Forestar Group
FOR
$1.51B
| $804K | ﹤0.01% |
38,592
+438
| +1% | +$8.56K |
|
2760
Aprea Therapeutics
APRE
$8.05M
| $803K | ﹤0.01% |
+875
| New | +$482K |
|
2761
Transmedics
TMDX
$2.91B
| $802K | ﹤0.01% |
42,187
+32,416
| +332% | +$595K |
|
|
MRSN
2762
DELISTED
Mersana Therapeutics
MRSN
| $797K | ﹤0.01% |
5,563
+1,251
| +29% | +$91.5K |
|
2763
Parke Bancorp
PKBK
$405M
| $796K | ﹤0.01% |
34,497
-193
| -0.6% | -$4.15K |
|
|
CATC
2764
DELISTED
CAMBRIDGE BANCORP
CATC
| $796K | ﹤0.01% |
9,926
-6,335
| -39% | -$494K |
|
|
CFMS
2765
DELISTED
Conformis, Inc. Common Stock
CFMS
| $795K | ﹤0.01% |
21,182
-1,728
| -8% | -$81.9K |
|
2766
Investar Holding Corp
ISTR
$414M
| $788K | ﹤0.01% |
32,835
-167
| -0.5% | -$4.11K |
|
2767
BlueLinx
BXC
$706M
| $784K | ﹤0.01% |
54,974
-2,220
| -4% | -$45.5K |
|
2768
RGC Resources
RGCO
$228M
| $784K | ﹤0.01% |
27,437
-335
| -1% | -$9.71K |
|
2769
Timberland Bancorp
TSBK
$351M
| $784K | ﹤0.01% |
26,359
-169
| -0.6% | -$4.73K |
|
2770
Syndax Pharmaceuticals
SNDX
$1.82B
| $783K | ﹤0.01% |
89,156
-59,832
| -40% | -$439K |
|
2771
Dianthus Therapeutics
DNTH
$6.09B
| $782K | ﹤0.01% |
3,222
-104
| -3% | -$19.4K |
|
2772
Genie Energy
GNE
$383M
| $778K | ﹤0.01% |
100,703
-2,134
| -2% | -$16.7K |
|
2773
Tiptree Inc
TIPT
$675M
| $778K | ﹤0.01% |
95,543
-642
| -0.7% | -$4.91K |
|
|
DLA
2774
DELISTED
Delta Apparel Inc.
DLA
| $777K | ﹤0.01% |
24,964
+15,813
| +173% | +$423K |
|
|
EGLE
2775
DELISTED
Eagle Bulk Shipping Inc.
EGLE
| $776K | ﹤0.01% |
24,117
-275
| -1% | -$8.46K |
|
Similar funds
VFT
Nuveen's Q4 2019 Portfolio in Review
As of Q4 2019, Nuveen held 3,331 positions worth $264B, up 6.7% from $247B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Nuveen's Q4 2019 filing shows 118 new, 1,090 increased, 1,840 reduced and 95 closed positions. Its largest new stake was iShares iBoxx $ Investment Grade Corporate Bond ETF: 8,077,161 shares worth $1.03B. The largest sale was Cisco, an estimated $474M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Nuveen's largest Q4 2019 buy was iShares iBoxx $ Investment Grade Corporate Bond ETF: 8,077,161 shares worth $1.03B.
- Nuveen added most to Bristol-Myers Squibb in Q4 2019, an estimated $649M increase.
- Nuveen's biggest Q4 2019 reduction was Cisco, cutting an estimated $474M.
- Nuveen fully exited Celgene Corp in Q4 2019, selling an estimated $421M.
- Nuveen's ten largest holdings make up 19% of its $264B portfolio in Q4 2019.
- Nuveen opened 118 new positions and closed 95 in Q4 2019.
- Nuveen's portfolio value rose 6.7% quarter-over-quarter to $264B.
Based on Nuveen's 13F filing for Q4 2019, filed 14 Feb 2020.